09/19/2025
Diversity in clinical trials isn’t just a statistic, it’s essential to ensuring research findings are relevant and equitable for every patient.
At Mary Bird Perkins Cancer Center, we are committed to rebuilding our clinical trials program from the ground up with diverse enrollment as a core priority. Under the leadership of Victor Lin, MD, PhD, medical director of Clinical Research and Genetics, we are taking concrete steps to expand access and improve representation, supported by a $400,000 grant from the Gilead Foundation.
📖 Read more about our approach and vision for the future in this Association of Cancer Care Centers Buzz feature:
👉 https://bit.ly/4ntebwh
About 85% of current participants in cancer clinical trials are White middle-class men. This lack of diversity results in findings that are not necessarily replicable to all patients.
Leaders at Mary Bird Perkins Cancer Center are addressing this disparity by rebuilding their clinical trials program from the ground up, with diverse enrollment a cornerstone of their philosophy.
To learn more about Mary Bird Perkins’ approach to clinical trials and the center’s plans for their $400,000 grant from the Gilead Foundation, ACCCBuzz spoke with Victor Lin, MD, PhD, medical director of Clinical Research and Genetics.
Read more at https://hubs.li/Q03JNSkx0